BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $286,000 | -36.0% | 27,000 | -1.8% | 0.02% | -21.7% |
| Q1 2022 | $447,000 | +16.1% | 27,500 | -1.2% | 0.02% | +9.5% |
| Q4 2021 | $385,000 | -5.4% | 27,824 | -1.8% | 0.02% | -8.7% |
| Q3 2021 | $407,000 | -9.2% | 28,324 | 0.0% | 0.02% | -14.8% |
| Q2 2021 | $448,000 | +52.9% | 28,324 | -1.7% | 0.03% | +92.9% |
| Q1 2021 | $293,000 | +5.8% | 28,824 | -22.5% | 0.01% | 0.0% |
| Q4 2020 | $277,000 | +307.4% | 37,200 | +88.8% | 0.01% | +133.3% |
| Q3 2020 | $68,000 | +240.0% | 19,700 | +369.0% | 0.01% | +200.0% |
| Q2 2020 | $20,000 | – | 4,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |